Table 2 |
|||||
|
Clinical characteristics of latent CD – patient chart review. |
|||||
|
EMA; N = 38 |
AGA; N = 36 |
TTGA; N = 38 |
Total; N = 112 |
Total Weighted N = 3,736 |
|
|
|
|||||
|
Background data |
|||||
|
|
|||||
|
Females |
26 (68) |
24 (67) |
25 (66) |
75 (67) |
- |
|
|
|||||
|
Age at first biopsy: median, range (years) |
13 (2–80) |
34 (1–91) |
34 (1–75) |
29 (1–91) |
- |
|
|
|||||
|
Year of biopsy, median* |
2003 |
2001 |
2006 |
2004 |
- |
|
|
|||||
|
Reported heredity for CD |
12 (32) |
7 (19) |
6 (16) |
25 (22) |
20% |
|
|
|||||
|
Other diseases |
|||||
|
|
|||||
|
Diabetes Mellitus, type 1 |
3 (8) |
1 (3) |
4 (10) |
8 (7) |
3% |
|
|
|||||
|
Depression |
1 (3) |
4 (11) |
8 (21) |
13 (12) |
11% |
|
|
|||||
|
Thyroid disease |
2 (5) |
3 (8) |
7 (18) |
12 (11) |
9% |
|
|
|||||
|
Liver disease or increased liver enzymes |
3 (8) |
4 (11) |
4 (10) |
11 (10) |
11% |
|
|
|||||
|
Symptoms |
|||||
|
|
|||||
|
Any gastrointestinal symptom# |
31 (82) |
32 (89) |
32 (84) |
95 (85) |
88% |
|
|
|||||
|
Diarrhea |
16 (42) |
18 (50) |
17 (45) |
51 (46) |
49% |
|
|
|||||
|
Weight loss/growth failure |
9 (24) |
7 (20) |
7 (18) |
23 (20) |
20% |
|
|
|||||
|
Abdominal pain |
14 (37) |
18 (50) |
18 (47) |
50 (45) |
49% |
|
|
|||||
|
Constipation |
10 (26) |
4 (11) |
6 (16) |
20 (18) |
12% |
|
|
|||||
|
Fatigue |
6 (16) |
6 (17) |
5 (13) |
17 (15) |
16% |
|
|
|||||
|
Laboratory data |
|||||
|
|
|||||
|
Anemia and/or iron-deficiency |
5 (13) |
12 (33) |
12 (32) |
29 (26) |
32% |
|
|
|||||
|
Folic acid deficiency |
2 (5) |
0 (0) |
4 (10) |
6 (5) |
1% |
|
|
|||||
|
B12-deficiency |
4 (10) |
2 (6) |
5 (13) |
11 (10) |
6% |
|
|
|||||
|
Erythrocyte sedimentation rate, increased |
0 (0) |
2 (6) |
3 (8) |
5 (4) |
5% |
|
|
|||||
|
Percentages are given within brackets. Although latent CD was evaluated in 120 individuals, data on symptoms and signs (± laboratory measures) were only available in 112 individuals (93.3%). EMA = Endomysial antibodies. AGA = Antigliadin antibodies. TTGA = Tissue transglutaminase antibodies. Weighted percentages were estimated to mirror the full sample of study participants. *Only for year of biopsy was there a statistically significant difference according to CD serology subtype when we corrected for multiple testing (Bonferroni correction [20]. There was no statistically significant difference in prevalence of any symptom or sign according to CD serology subtype. #Weight loss was included among "any GI symptom". Also reflux symptoms (not listed above); nausea and abdominal gases were included among "any GI symptoms". Additional information: Two individuals had a diagnosis of inflammatory bowel disease (IBD), both were positive for TTGA. Another two individuals had a diagnosis of dermatitis herpetiformis, both were positive for EMA. |
|||||
|
Ludvigsson et al. BMC Gastroenterology 2009 9:57 doi:10.1186/1471-230X-9-57 |
|||||
